Patient-Executed, Clinician-Confirmed Diuretic Titration in Pulmonary Artery Pressure-Guided Heart Failure (SURPASS-HF)

Non-randomized, prospective, single-center feasibility study. Participants who complete the study function as their own comparative controls. Planned screening of 30 patients with planned enrollment of 15; actual enrollment was 21. Per protocol addendum, a retrospective chart-review cohort (N=31 patients with a CardioMEMS device and 6 months of data from implant date, not included in the prospective arm) serves as a control/baseline comparison using data already in the medical record; no additional visits, questionnaires, or blood draws were required for that cohort. Adverse events were pre-defined in the protocol as: hypokalemia, hospitalization, syncope, urgent clinic/ER visit, and acute kidney injury.